Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01891019 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in the Treatment of Chronic Plaque Psoriasis.
A Phase 2 study of Psoriasis, Plaque-type, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01891019: Completed Phase 2 study of Psoriasis, Plaque-type, sponsored by Wake Forest University.
NCT01891019 is a Phase 2 study of Psoriasis, Plaque-type that has completed, run by Wake Forest University. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01891019, a Phase 2 study of Psoriasis, Plaque-type, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to obtain information on the effectiveness of thalidomide in psoriasis.
Primary Outcome
The change from Baseline to Week 12 (or end of treatment) in the composite score (PASI) of the signs of psoriasis (erythema, scaling, plaque thickness).
Conditions Studied
Interventions
- DRUG Thalidomide oral
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2003-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT01891019 record still lists
NCT01891019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Psoriasis, Plaque-type appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide oral is the first listed.
NCT01891019 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01891019 about?
NCT01891019 is a clinical study titled "Thalidomide in the Treatment of Chronic Plaque Psoriasis.". The objective of this study is to obtain information on the effectiveness of thalidomide in psoriasis.
What is the current status of trial NCT01891019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2003-04. Estimated completion is 2009-06.
What conditions does trial NCT01891019 study?
This clinical trial studies the following conditions: Psoriasis, Plaque-type.
What interventions are being tested in trial NCT01891019?
The interventions under investigation include: Thalidomide oral (DRUG).
Who is sponsoring clinical trial NCT01891019?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01891019 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01891019's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia